ZNF384 and acute lymphoblastic leukemia: We further evaluated therapeutic potential of doxorubicin in EP300-ZNF384 positive B-ALL cells in vitro and in vivo, pointing to that targeted therapies involving anthracyclines may produce a favorable outcome in patients with EP300-ZNF384.